BREMELANOTIDE PT-141

LIBIDO AND ERECTION NEUROPEPTIDE

Purity: >98% (HPLC on request)
Molecular Formula: $C_{50}H_{68}N_{14}O_{10}$
Molecular Weight: 1025.2

Sequence:

DESCRIPTION

Bremelanotide(PT-141) was developed from the peptide hormone Melanotan II. In initial testing, Melanotan II induced darkening of skin pigment, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Further testing in animals showed Bremelanotide to induce lordosis (a sexual mating behavior) and subsequently tested for its effect in humans. Although, most of the research has been targeted to women with female sexual dysfunction and it is effective medication in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system. It is estimated that 43% of women (30 million is the US) suffer from sexual dysfunction and 30 million men suffer from ED, with incidence increasing 2-3 fold between ages 40-70. Bremelanotide currently has no contraindications and is 80% effective in people who don't respond to Viagra or Cialis.

SUGGESTED PROTOCOL

Content & Potency: 10mg/ml subcutaneous injection provided in a 2ml vial.
Suggested dosage: Inject 0.2mL subcutaneously as needed, 30 minutes prior to sexual activity.The initial dose will establish a time frame for response. Men should start at 0.1ml and titrate up to and not exceed 0.2ml. Women should start at 0.2ml dosing protocol.

CLINICAL RESEARCH

Melanocortins in the treatment of male and female sexual dysfunction

Shadiack AM, Sharma SD, Earle DC, Spana C, Hallam TJ

Abstract: Melanocortinergic agents are currently being investigated for a possible therapeutic role in male and female sexual dysfunction. These investigations were sparked by findings that systemic administration of a synthetic analog of alpha-MSH, MT-II, causes penile erections in a variety of species, including humans. Several other melanocortinergic agents including HP-228, THIQ, and bremelanotide (PT 141) have since been shown to have erectogenic properties thought to be due to binding to melanocortin receptors in the central nervous system, particularly the hypothalamus. Bremelanotide, a nasally administered synthetic peptide, is the only melanocortinergic agent that has been clinically studied in both males and females. Data from Phase II clinical trials of bremelanotide support the use of melanocortin based therapy for erectile dysfunction. Studies using animal models have demonstrated that precopulatory behaviors in female rats analogous to sexual arousal are evoked, and preliminary clinical data also suggest a role in promoting sexual desire and arousal in women. Based on bremelanotide clinical experience, administration of a melanocortin agonist is well tolerated and not associated the hypotension observed with phosphodiesterase-5 inhibitors currently used to treat erectile dysfunction. This review discusses investigations of melanocortin agonists for the treatment of sexual dysfunction with emphasis on proposed sites and mechanisms of action in the central nervous system that appear to be involved in melanocortinergic modulation of sexual function.

A full copy of all trials are available from EVEXIAS Health Solutions.
Please contact us for more info.

EVEXIAS Health Solutions| 844-EVEXIAS | info@evexias.com